Kodiak Sciences. has been granted a patent for a protein construct that combines an antagonist IL-6 antibody with a VEGF trap. This invention includes specific amino acid sequences for the antibody’s heavy and light chains, and it outlines therapeutic applications for treating various diseases. GlobalData’s report on Kodiak Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kodiak Sciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Kodiak Sciences's grant share as of July 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Antagonistic il-6 antibodies fused with vegf trap proteins
The granted patent US12071476B2 presents a novel protein construct that combines an antagonist IL-6 antibody with a VEGF trap, aimed at addressing neovascular retinal diseases. The construct is characterized by specific amino acid sequences for both the heavy and light chains, which can include various combinations of complementarity determining regions (CDRs) as outlined in the patent claims. The heavy chain may feature a VEGF trap positioned either at the N-terminal end or between the hinge region and the CH1 domain. Additionally, the patent describes conjugates formed from this protein construct, which can be covalently linked to polymers, enhancing their therapeutic potential.
The patent further details methods for treating neovascular retinal diseases by administering the described conjugates to patients. These methods emphasize the identification of patients in need and the administration of the conjugate, which is designed to mitigate angiogenesis and inflammation associated with such diseases. The conjugates are specified to have a molecular weight ranging from approximately 350,000 to 1,900,000 Daltons, and the patent includes various structural configurations for the protein constructs and conjugates, including specific sequences for the VEGF trap and potential mutations to enhance efficacy. Overall, the patent outlines a comprehensive approach to developing dual inhibitors targeting IL-6 and VEGF, with implications for treating serious ocular conditions.
To know more about GlobalData’s detailed insights on Kodiak Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
